Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

AD109 met the primary endpoint, mean change in apnea-hypopnea index (AHI, p=0.001) at 26 weeks, across a broad range of people with mild, moderate and severe obstructive sleep apnea Study ...

Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data ...

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep apnoea pill.

The ResMed Inc (ASX: RMD) share price is falling on Tuesday. What's going on? Let's dig deeper into things and find ...

ACE indicates angiotensin-converting enzyme; AHI, apnea-hypopnea index; BMI, body mass index; BP, blood pressure; IQR, interquartile range; and OSA, obstructive sleep apnea. Spironolactone prescribed ...

with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an AHI value below 20. The study features a differentiated ...

Frontoparietal cerebrovascular pathology is linked to oxygenation during REM sleep, indicating possible connection to Alzheimer Disease.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

The main goal was to measure at six months the change in the apnea-hypopnea index, a scale used to measure the breathing reductions or interruptions during sleep (the higher the score, the more ...